Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of terminal liver diseases including liver cirrhosis and hepatocellular carcinoma. Growing evidence demonstrates the critical importance of inflammation in the pathogenesis of NAFLD. For instance, nutrient overload triggers inflammation, which can act through stimulating lipogenesis to increase hepatic steatosis. The latter, in turn, can exacerbate liver inflammation and progress to non-alcoholic steatohepatitis (NASH). However, the precise mechanisms underlying the interaction between hepatic steatosis and liver inflammation remain to be elucidated. Thus, the long-term goal of the proposed research is to dissect the metabolic and inflammatory mechanisms underlying NAFLD in order that novel evidence-based approaches can be developed for preventing and/or treating NASH. As a G-protein-coupled receptor, adenosine 2A receptor (A2AR) is abundantly expressed in immune cells and exhibits powerful anti-inflammatory properties. A2AR is also highly expressed in hepatocytes, in which A2AR functions are largely unknown. For this project, the central hypothesis is that the A2AR in hepatocytes and macrophages protects against the development of different aspects of NAFLD in a cell-type-dependent manner. This hypothesis is based on the following novel findings: 1) A2AR deficiency in hepatocytes plays a more important role than A2AR deficiency in myeloid cells (macrophages) in exacerbating high-fat diet (HFD)- induced hepatic steatosis, which is associated with increased hepatic expression of lipogenic enzymes;2) A2AR deficiency exacerbates HFD-induced liver inflammation, which is likely attributed to increased macrophage/Kupffer cell proinflammatory activation;and 3) A2AR activation by a specific agonist protects mice from HFD-induced NAFLD. Thus, the goal of this project is to define a novel protective role for A2AR in NAFLD. For this purpose, mice that lack A2AR in hepatocytes and/or myeloid cells are generated.
For Specific Aim 1, in vivo experiments will be performed to examine the extent to which the A2AR in hepatocytes acts through inhibiting lipogenesis to protect against NAFLD. Moreover, cellular experiments will be performed to elucidate the involvement of SREBP1c and ChREBP in A2AR inhibition of lipogenic gene expression.
For Specific Aim 2, in vivo experiments will be performed to examine the extent to which the A2AR in macrophages or hepatocytes protects against NAFLD by suppressing liver inflammatory response.
For Specific Aim 3, in vivo experiments will be performed to define A2AR coordination of hepatocyte-macrophage crosstalk in NAFLD. Moreover, in vitro co-culture experiments will be performed to examine the extent to which factors generated by A2AR-deficient macrophages, i.e., TNF? and IL-6, stimulate hepatocyte lipogenesis, and the extent to which factors generated by A2AR-deficient hepatocytes, i.e., palmitate, stimulate macrophage proinflammatory activation. Together, the proposed research will illustrate a new paradigm on NAFLD, and provide the experimental basis for prevention and/or treatment of NASH by means of A2AR activation.

Public Health Relevance

Results from the proposed research will significantly advance the knowledge of the pathophysiology of NAFLD. Furthermore, the successful completion of this project will support the development of A2AR-based novel approaches for preventing and/or treating NASH, for which no effective treatment is currently available.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK095862-01A1
Application #
8504439
Study Section
Hepatobiliary Pathophysiology Study Section (HBPP)
Program Officer
Doo, Edward
Project Start
2013-04-15
Project End
2018-03-31
Budget Start
2013-04-15
Budget End
2014-03-31
Support Year
1
Fiscal Year
2013
Total Cost
$328,976
Indirect Cost
$78,851
Name
Texas Agrilife Research
Department
Nutrition
Type
Schools of Earth Sciences/Natur
DUNS #
847205713
City
College Station
State
TX
Country
United States
Zip Code
77843
Guo, Xin; Shu, Chang; Li, Honggui et al. (2017) Cyclic GMP-AMP Ameliorates Diet-induced Metabolic Dysregulation and Regulates Proinflammatory Responses Distinctly from STING Activation. Sci Rep 7:6355
Xu, Yiming; Wang, Yong; Yan, Siyuan et al. (2017) Regulation of endothelial intracellular adenosine via adenosine kinase epigenetically modulates vascular inflammation. Nat Commun 8:943
Qi, Ting; Chen, Yanming; Li, Honggui et al. (2017) A role for PFKFB3/iPFK2 in metformin suppression of adipocyte inflammatory responses. J Mol Endocrinol 59:49-59
Botchlett, Rachel; Woo, Shih-Lung; Liu, Mengyang et al. (2017) Nutritional approaches for managing obesity-associated metabolic diseases. J Endocrinol 233:R145-R171
Xu, Yiming; Wang, Yong; Yan, Siyuan et al. (2017) Intracellular adenosine regulates epigenetic programming in endothelial cells to promote angiogenesis. EMBO Mol Med 9:1263-1278
Yu, Jinsheng; Marsh, Sharon; Hu, Junbo et al. (2016) The Pathogenesis of Nonalcoholic Fatty Liver Disease: Interplay between Diet, Gut Microbiota, and Genetic Background. Gastroenterol Res Pract 2016:2862173
Yu, Jinsheng; Marsh, Sharon; Hu, Junbo et al. (2016) Gut Microbiota and Metagenomic Advancement in Digestive Disease. Gastroenterol Res Pract 2016:4703406
Zeng, Tianshu; Zhou, Jing; He, Linzheng et al. (2016) Blocking Nuclear Factor-Kappa B Protects against Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. PLoS One 11:e0149677
Chen, Lili; Zhao, Jiajia; Tang, Qingming et al. (2016) PFKFB3 Control of Cancer Growth by Responding to Circadian Clock Outputs. Sci Rep 6:24324
Botchlett, Rachel; Li, Honggui; Guo, Xin et al. (2016) Glucose and Palmitate Differentially Regulate PFKFB3/iPFK2 and Inflammatory Responses in Mouse Intestinal Epithelial Cells. Sci Rep 6:28963

Showing the most recent 10 out of 18 publications